PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.39
5.09M / 4.21M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-63.74%
Negative revenue growth while CX stands at 4.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-73.24%
Negative gross profit growth while CX is at 6.77%. Joel Greenblatt would examine cost competitiveness or demand decline.
-99.92%
Negative EBIT growth while CX is at 22.80%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-99.92%
Negative operating income growth while CX is at 22.80%. Joel Greenblatt would press for urgent turnaround measures.
-101.60%
Negative net income growth while CX stands at 229.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-102.14%
Negative EPS growth while CX is at 225.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-102.16%
Negative diluted EPS growth while CX is at 225.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.98%
Share reduction while CX is at 0.03%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.87%
Reduced diluted shares while CX is at 0.03%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-121.11%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-144.54%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while CX shows 4.99%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
1.96%
Inventory shrinking or stable vs. CX's 5.90%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
1.76%
Asset growth well under 50% of CX's 3.94%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.50%
We have a declining book value while CX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
1.28%
We have some new debt while CX reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-53.75%
We cut SG&A while CX invests at 0.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.